Robert Hauser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11533073/publications.pdf

Version: 2024-02-01

933447 1281871 3,342 11 10 11 citations h-index g-index papers 11 11 11 3826 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	10.2	94
2	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Annals of Clinical and Translational Neurology, 2020, 7, 1816-1830.	3.7	23
3	The Parkinson's progression markers initiative (PPMI) $\hat{a}\in$ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	3.7	330
4	Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. Journal of Parkinson's Disease, 2015, 5, 773-782.	2.8	5
5	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. JAMA - Journal of the American Medical Association, 2015, 313, 584.	7.4	192
6	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	5.7	1,278
7	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurology, The, 2011, 10, 415-423.	10.2	192
8	Wearingâ€off scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2169-2175.	3.9	101
9	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. New England Journal of Medicine, 2009, 361, 1268-1278.	27.0	830
10	End-of-dose Wearing Off in Parkinson Disease. Clinical Neuropharmacology, 2006, 29, 312-321.	0.7	78
11	Identification of motor and nonmotor wearingâ€off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. Movement Disorders, 2005, 20, 726-733.	3.9	219